open access
New opportunities in immunotherapy in multiple myeloma
Affiliations- Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland
open access
Abstract
Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the development of new drugs remains incurable. There are several antigens that are being assessed in preclinical and clinical settings, but the most studied of all is B-cell maturation antigen (BCMA). BCMA is a target for antibody conjugated with toxins (ADCs), bispecific engagers (BITEs), and modified autologous lymphocytes (CAR-T, chimeric antigen receptor T cells). Belantamab mafodotin (ADC, registered in the European Union), teclistamab (BITE) and two CAR-Ts: ide-cel (Food and Drug Administation-approved) and cilta-cel are the most studied therapies in myeloma. Immunotherapy will definitely change the treatment strategy of multiple myeloma and accelerate the fight against myeloma.
Abstract
Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the development of new drugs remains incurable. There are several antigens that are being assessed in preclinical and clinical settings, but the most studied of all is B-cell maturation antigen (BCMA). BCMA is a target for antibody conjugated with toxins (ADCs), bispecific engagers (BITEs), and modified autologous lymphocytes (CAR-T, chimeric antigen receptor T cells). Belantamab mafodotin (ADC, registered in the European Union), teclistamab (BITE) and two CAR-Ts: ide-cel (Food and Drug Administation-approved) and cilta-cel are the most studied therapies in myeloma. Immunotherapy will definitely change the treatment strategy of multiple myeloma and accelerate the fight against myeloma.
Keywords
immunotherapy, CAR-T, bispecific antibodies
About this articleTitle
New opportunities in immunotherapy in multiple myeloma
Journal
Issue
Article type
Review article
Pages
371-374
Page views
164
Article views/downloads
195
DOI
10.5603/AHP.2021.0070
Bibliographic record
Acta Haematol Pol 2021;52(4):371-374.
Keywords
immunotherapy
CAR-T
bispecific antibodies
Authors
Dominik Dytfeld
References (12)- Malek E, de Lima M, Letterio JJ, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016; 30(5): 341–348.
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024): 1565–1570.
- Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013; 62(1): 39–49.
- Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7): 621–631.
- Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018; 379(19): 1811–1822.
- Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21(2): 207–221.
- Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020; 38(8): 775–783.
- Usmani SZ, Mateos MV, Nahi H, et al. Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). J Clin Oncol. 2020; 38(15_suppl): 100.
- Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8): 705–716.
- Madduri D, Berdeja J, Usmani S, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020; 136(Suppl 1): 22–25.
- Mailankody S, Matous J, Liedtke M, et al. Universal: an allogeneic first-inhuman study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma. Blood. 2020; 136(Suppl 1): 24–25.
- Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020; 135(15): 1232–1243.